盐酸缬更昔洛韦片是什么呢？

It is a pink oval film-coated oral tablet. The main ingredient is valganciclovir hydrochloride. Its chemical name is: 1. L-valine, -2[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxy-propyl ester, monohydrochloride.

Valganciclovir hydrochloride tablets are suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients. Valganciclovir hydrochloride tablets are sensitive to human viruses including human cytomegalovirus (HCMV), and valganciclovir hydrochloride tablets are sensitive to herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV) and hepatitis B virus.

Valganciclovir Hydrochloride Tablets can inhibit viral activity mainly by inhibiting the synthesis of viral DNA: Valganciclovir Hydrochloride Tablets competitively inhibit viral DNA polymerase, preventing deoxyguanylate triphosphate from binding to DNA. The ganciclovir triphosphate in Valganciclovir Hydrochloride Tablets binds to viral DNA, terminating or limiting the elongation of the viral DNA chain. The IC50 of the antiviral effect of valganciclovir hydrochloride tablets on CMV in vitro ranges from 0.08μM (0.02ug/ml) to 14μM (3.5ug/ml).

Usage and dosage of Valganciclovir Hydrochloride Tablets: Note: The basic requirement to avoid drug overdose is to strictly follow the recommended dosage. Standard dosage: Valganciclovir hydrochloride tablets are administered orally and should be taken with food. Valganciclovir hydrochloride tablets can be rapidly converted into ganciclovir in large amounts. The bioavailability of valganciclovir hydrochloride tablets as measured by ganciclovir is 10 times higher than that of ganciclovir capsules, so the dosage and usage instructions of valganciclovir hydrochloride tablets described below should be strictly followed.

Induction therapy of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity. Maintenance treatment of CMV retinitis: After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis. Prevention of CMV infection in transplant patients: For patients who have received solid organ transplants, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.